



Advanced Chemical Industries Limited


Condensed Interim Financial Statements
1st quarter ended report 2024-2025
for the three months period ended on 30 September 2024


Advanced Chemical Industries Limited
Statement of financial position
Unaudited

	Note	Figures in '000' Taka	
		As at 30 September 2024	As at 30 June 2024
Assets			
Property, plant and equipment	2	18,439,514	17,951,455
Right-of-use assets		676,691	688,959
Investments	3	3,645,864	3,632,438
Intangible assets		10,428	10,644
Biological assets		52,816	52,493
Non-current assets		22,825,313	22,335,988
Inventories	4	8,969,573	8,710,393
Trade receivables	5	4,010,529	4,036,880
Other receivables		872,255	743,954
Inter-company receivables	6	36,459,896	34,127,510
Current tax assets		1,051,088	1,001,981
Advances, deposits and prepayments	7	1,745,231	1,918,300
Cash and cash equivalents		1,572,427	1,243,417
Current assets		54,680,999	51,782,435
Total assets		77,506,311	74,118,423
Equity			
Share capital		762,056	762,056
Share premium		402,310	402,310
Merger consideration shares reserve		56,854	56,854
Reserves		4,867,435	4,877,506
Retained earnings		19,496,027	18,765,010
Total equity		25,584,682	24,863,737
Liabilities			
Employee benefits	8	1,664,166	1,558,453
Long term borrowings	9	1,632,161	1,692,941
Non-current portion of lease liabilities		489,410	488,415
Deferred tax liabilities		264,149	300,417
Non-current liabilities		4,049,886	4,040,226
Bank overdraft		7,744,077	6,059,933
Loans and borrowings	10	28,365,149	27,235,242
Current portion of lease liabilities		187,410	187,024
Trade payables		1,392,542	1,419,329
Inter-company payables	11	5,601,347	6,261,434
Other payables	12	4,572,888	4,043,278
Unclaimed/unpaid dividend account		8,330	8,222
Current liabilities		47,871,743	45,214,461
Total liabilities		51,921,629	49,254,687
Total equity and liabilities		77,506,311	74,118,423
Net asset value (NAV) per share (in Taka)		334.87	325.44


Managing Director


Director



Chief Financial Officer


Company Secretary


Advanced Chemical Industries Limited
Statement of profit or loss
Unaudited

	Note	Figures in '000' Taka	
		For the 1st quarter ended from	
		July 2024	July 2023
		to September 2024	to September 2023
Revenue	13	10,138,859	8,734,403
Cost of sales	14	(6,244,677)	(5,085,503)
Gross profit		3,894,181	3,648,899
Administrative, selling and distribution expenses	15	(2,673,090)	(2,824,735)
Other income		33,100	104,591
Operating profit		1,254,190	928,755
Net finance costs		(276,764)	(100,298)
Profit before contribution to WPPF		977,426	828,457
Contribution to WPPF		(48,871)	(41,423)
Profit before tax		928,555	787,034
Income tax expense		(197,538)	(218,901)
Profit after tax		731,017	568,134
Earnings per share			
Basic and diluted earnings per share (EPS) (in Taka)		9.57	7.44


**Financials of July to September 2024 include effect of merger with Premiaflex Plastics Limited.*




Managing Director



Director



Chief Financial Officer



Company Secretary

Advanced Chemical Industries Limited
Statement of profit or loss and other comprehensive income
Unaudited

	Figures in '000' Taka	
	For the 1st quarter ended from	
	July 2024 to September 2024	July 2023 to September 2023
Profit after tax	731,017	568,134
Other comprehensive income:		
Change in fair value of FVOCI financial assets	(11,848)	(5,930)
Income tax on FVOCI financial assets	1,777	593
Other comprehensive income, net of tax	(10,071)	(5,337)
Total comprehensive income	720,946	562,797

Advanced Chemical Industries Limited
Statement of changes in equity
Unaudited

	Figures in '000' Taka							
	For the 1st quarter ended from July 2024 to September 2024							
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
Balance at 1 July 2024	762,056	402,310	56,854	1,671	291,665	4,584,170	18,765,010	24,863,737
Total comprehensive income								
Profit after tax	-	-	-	-	-	-	731,017	731,017
Other comprehensive income, net of tax	-	-	-	-	(10,071)	-	-	(10,071)
Total comprehensive income	-	-	-	-	(10,071)	-	731,017	720,946
Transaction with owners of the Company								
Stock dividend	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-
Total transactions with owners of the Company	-	-	-	-	-	-	-	-
Balance at 30 September 2024	762,056	402,310	56,854	1,671	281,594	4,584,170	19,496,027	25,584,682
	For the period up to 1st quarter from July 2023 to September 2023							
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
	Balance at 1 July 2023	762,056	402,310	-	1,671	393,444	4,157,372	15,703,474
Total comprehensive income								
Profit after tax	-	-	-	-	-	-	568,134	568,134
Other comprehensive income, net of tax	-	-	-	-	(5,337)	-	-	(5,337)
Total comprehensive income	-	-	-	-	(5,337)	-	568,134	562,797
Transaction with owners of the Company								
Stock dividend	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-
Total transactions with owners of the Company	-	-	-	-	-	-	-	-
Balance at 30 September 2023	762,056	402,310	-	1,671	388,108	4,157,372	16,271,608	21,983,125

Advanced Chemical Industries Limited
Statement of cash flows
Unaudited

	Figures in '000' Taka	
	For the 1st quarter ended from	
	July 2024 to September 2024	July 2023 to September 2023
Cash flows from operating activities		
Cash receipts from customers and others	10,043,053	8,718,830
Cash paid to suppliers and employees	(8,643,636)	(7,733,643)
Cash generated from / (used in) operating activities	1,399,416	985,187
Paid to WPPF	(12,168)	(13,439)
Finance costs paid	(79,704)	(76,860)
Income tax paid	(281,136)	(204,748)
	(373,008)	(295,047)
Net cash from / (used in) operating activities*	16	1,026,408
Cash flows from investing activities		
Acquisition of property, plant and equipment	(227,747)	(162,677)
Payments for capital work-in-progress	(422,467)	(252,996)
Sale proceeds from property, plant and equipment	1,030	32
Purchase of biological assets	(1,596)	(1,694)
Investment	(25,275)	(2,400)
Net cash from / (used in) investing activities	(676,055)	(419,735)
Cash flows from financing activities		
Inter-company debts received/(paid)	(3,040,869)	(1,703,858)
Payment for lease liabilities	(47,367)	(45,745)
Short-term bank loan received/(paid)	1,349,152	1,570,844
Long-term bank loan received/(paid)	33,313	(17,195)
Net cash from / (used in) financing activities	(1,705,771)	(195,954)
Net increase / (decrease) in cash and cash equivalents	(1,355,418)	74,452
Opening cash and cash equivalents	(4,816,516)	(4,667,536)
Effect of movements in exchange rates on cash held	284	2,305
Closing cash and cash equivalents	(6,171,650)	(4,590,779)
Closing balance represents		
Cash and cash equivalents	1,572,427	1,453,792
Bank overdraft	(7,744,077)	(6,044,571)
	(6,171,650)	(4,590,779)
Net operating cash flow per share (NOCFPS) (in Taka)	13.43	9.03

*See Note 16 for reconciliation of net operating cash flow.

Advanced Chemical Industries Limited
Consolidated statement of financial position
Unaudited

	Note	Figures in '000' Taka	
		As at 30 September 2024	As at 30 June 2024
Assets			
Property, plant and equipment	2 (a)	34,265,172	33,811,986
Right-of-use assets		3,154,271	3,184,834
Equity-accounted investees		3,055,869	2,920,871
Other investments		1,094,245	1,131,177
Intangible assets		1,406,680	1,415,465
Biological assets		52,816	52,493
Deferred tax assets		580,887	532,202
Non-current assets		43,609,940	43,049,028
Inventories	4 (a)	22,120,687	21,290,152
Trade receivables	5 (a)	19,028,217	17,639,830
Other receivables		1,155,196	1,021,788
Advances, deposits and prepayments	7 (a)	5,900,808	4,631,596
Current tax assets		710,857	675,485
Short term investments		199,499	196,492
Cash and cash equivalents		5,312,846	5,590,360
Current assets		54,428,111	51,045,703
Total assets		98,038,051	94,094,731
Equity			
Share capital		762,056	762,056
Share premium		1,254,116	1,254,116
Merger consideration shares reserve		56,854	56,854
Reserves		6,003,821	6,069,477
Accumulated loss		(1,600,233)	(1,176,671)
Equity attributable to owners of the Company		6,476,613	6,965,832
Non-controlling interests		1,552,995	1,591,894
Total equity		8,029,608	8,557,727
Liabilities			
Employee benefits	8 (a)	2,121,816	1,986,827
Long term borrowings	9 (a)	6,394,868	6,943,562
Non-current portion of lease liabilities		2,527,162	2,520,229
Non-current liabilities		11,043,846	11,450,618
Bank overdraft		10,601,358	8,697,868
Loans and borrowings	10 (a)	51,749,684	48,020,336
Current portion of lease liabilities		591,747	569,534
Trade payables		6,501,644	7,424,167
Other payables	12 (a)	9,510,484	9,364,909
Unclaimed/unpaid dividend account		9,680	9,572
Current liabilities		78,964,597	74,086,386
Total liabilities		90,008,443	85,537,004
Total equity and liabilities		98,038,051	94,094,731
Net asset value (NAV) per share (in Taka)	18	84.77	91.17


Managing Director


Director


Chief Financial Officer


Company Secretary

Advanced Chemical Industries Limited
Consolidated statement of profit or loss
Unaudited

Figures in '000' Taka


	Note	For the 1st quarter ended from	
		July 2024 to September 2024	July 2023 to September 2023
Revenue	13 (a)	29,709,695	30,405,296
Cost of sales	14 (a)	(22,224,219)	(23,083,086)
Gross profit		7,485,476	7,322,210
Administrative, selling and distribution expenses	15 (a)	(5,401,832)	(5,584,536)
Other income/ (loss)		83,034	143,032
Operating profit		2,166,678	1,880,707
Share of the profit of equity accounted investees		110,091	157,600
Net finance costs		(2,126,202)	(1,534,474)
Profit before contribution to WPPF		150,567	503,833
Contribution to WPPF		(84,049)	(75,909)
Profit before tax		66,518	427,924
Income tax expense		(535,661)	(569,018)
Profit/ (loss) after tax		(469,144)	(141,094)
Profit/ (loss) attributable to:			
Owners of the Company		(423,563)	(157,892)
Non-controlling interests		(45,581)	16,798
Profit/ (loss) after tax		(469,144)	(141,094)
Earnings per share			
Basic and diluted earnings per share (EPS) (in Taka)	18	(5.54)	(2.07)



Managing Director



Director



Chief Financial Officer



Company Secretary

Advanced Chemical Industries Limited
Consolidated statement of profit or loss and other comprehensive income
Unaudited

	Figures in '000' Taka	
	For the 1st quarter ended from	
	July 2024 to September 2024	July 2023 to September 2023
Profit/ (loss) after tax	(469,144)	(141,094)
Other comprehensive income:		
Foreign operations - foreign currency translation differences	(70,302)	(38,067)
Change in fair value of FVOCI financial assets	10,620	(6,765)
Income tax on other comprehensive income	(1,593)	677
Other comprehensive income, net of tax	(61,275)	(44,156)
Total comprehensive income	(530,419)	(185,250)
Total comprehensive income attributable to:		
Owners of the Company		
Profit/ (loss) after tax	(423,563)	(157,892)
Other comprehensive income	(65,656)	(38,479)
	(489,219)	(196,370)
Non-controlling interests		
Profit/ (loss) after tax	(45,581)	16,798
Other comprehensive income	4,381	(5,677)
	(41,200)	11,120
Total comprehensive income	(530,419)	(185,250)

Advanced Chemical Industries Limited
Consolidated statement of changes in equity
Unaudited

Figures in '000' Taka
For the 1st quarter ended from July 2024 to September 2024

	Attributable to owners of the Company									Non-controlling Interests	Total equity
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Accumulated loss	Total		
Balance at 1 July 2024	762,056	1,254,116	56,854	1,671	(57,081)	272,821	5,852,066	(1,176,671)	6,965,832	1,591,894	8,557,727
Total comprehensive income											
Profit/ (loss) after tax	-	-	-	-	-	-	-	(423,563)	(423,563)	(45,581)	(469,144)
Other comprehensive income, net of tax	-	-	-	-	(65,337)	(319)	-	-	(65,656)	4,381	(61,275)
Total comprehensive income	-	-	-	-	(65,337)	(319)	-	(423,563)	(489,219)	(41,200)	(530,419)
Transaction with owners of the Company											
Stock dividend	-	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-	-	-	-
Capital contribution by non-controlling interests	-	-	-	-	-	-	-	-	-	2,300	2,300
Total transactions with owners of the Company	-	-	-	-	-	-	-	-	-	2,300	2,300
Balance at 30 September 2024	762,056	1,254,116	56,854	1,671	(122,418)	272,502	5,852,066	(1,600,233)	6,476,613	1,552,995	8,029,608

For the period up to 1st quarter from July 2023 to September 2023

	Attributable to owners of the Company									Non-controlling Interests	Total equity
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2023	762,056	1,254,116	-	1,671	(120,987)	389,978	5,860,112	515,470	8,662,417	1,884,856	10,547,273
Total comprehensive income											
Profit/ (loss) after tax	-	-	-	-	-	-	-	(157,892)	(157,892)	16,798	(141,094)
Other comprehensive income, net of tax	-	-	-	-	(32,758)	(5,721)	-	-	(38,479)	(5,677)	(44,156)
Total comprehensive income	-	-	-	-	(32,758)	(5,721)	-	(157,892)	(196,370)	11,120	(185,250)
Transaction with owners of the Company											
Stock dividend	-	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-	-	-	-
Total transactions with owners of the Company	-	-	-	-	-	-	-	-	-	-	-
Balance at 30 September 2023	762,056	1,254,116	-	1,671	(153,745)	384,257	5,860,112	357,579	8,466,046	1,895,977	10,362,023

Advanced Chemical Industries Limited
Consolidated statement of cash flows
Unaudited

	Figures in '000' Taka	
	For the 1st quarter ended from	
	July 2024 to September 2024	July 2023 to September 2023
Cash flows from operating activities		
Cash receipts from customers and others	27,389,349	28,518,884
Cash paid to suppliers and employees	(29,556,649)	(29,394,862)
Cash generated from / (used in) operating activities	(2,167,301)	(875,978)
Paid to WPPF	(29,615)	(22,984)
Finance costs paid	(1,937,751)	(1,136,008)
Income tax paid	(607,844)	(577,024)
	(2,575,210)	(1,736,016)
Net cash from / (used in) operating activities *	16 (a)	(4,742,511)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(341,547)	(215,410)
Payments for capital work-in-progress	(526,423)	(1,520,568)
Sale proceeds from property, plant and equipment	5,564	32
Purchase of biological assets	(1,596)	(1,694)
Short term investments	(3,008)	2,660,687
Long term investments	(25,275)	(2,400)
Net cash from / (used in) investing activities	(892,285)	920,646
Cash flows from financing activities		
Dividend paid to non-controlling interests	-	(5)
Payment for lease liabilities	(141,671)	(119,681)
Short-term bank loan received/(paid)	3,952,661	696,072
Long-term bank loan received/(paid)	(358,324)	415,509
Net cash from / (used in) financing activities	3,452,665	991,895
Net increase / (decrease) in cash and cash equivalents	(2,182,130)	(699,453)
Opening cash and cash equivalents	(3,107,509)	(3,154,964)
Effect of movements in exchange rates on cash held	1,127	4,327
Closing cash and cash equivalents	(5,288,512)	(3,850,089)
Closing balance represents		
Cash and cash equivalents	5,312,846	5,102,376
Bank overdraft	(10,601,358)	(8,952,465)
	(5,288,512)	(3,850,089)
Net operating cash flow per share (NOCFPS) (in Taka)	18	(62.07)
		(34.19)

*See Note 16(a) for reconciliation of consolidated net operating cash flow.

Advanced Chemical Industries Limited
Notes to the financial statements
As at and for the 1st quarter ended on 30 September 2024
Unaudited

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2023 to 30 June 2024. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

2	Property, plant and equipment	30 September 2024	Figures in '000' Taka
		Taka	30 June 2024
		Taka	Taka
	Opening balance	23,093,157	18,382,467
	Additions during the period	662,676	1,755,503
	Disposals and adjustments	(14,777)	(39,809)
	Adjustment for Merger	-	2,994,996
	Accumulated depreciation	(5,301,542)	(5,141,702)
	Closing balance	18,439,514	17,951,455
2 (a)	Consolidated property, plant and equipment		
	Opening balance	45,716,051	41,925,146
	Additions during the period	882,849	3,837,166
	Disposals and adjustments	(26,006)	(46,261)
	Accumulated depreciation	(12,307,723)	(11,904,065)
	Closing balance	34,265,172	33,811,986
3	Investments		
	Investment in subsidiaries	1,877,438	1,877,638
	Investment in joint ventures	185,000	185,000
	Investment in associates	1,231,006	1,206,098
	Investment in shares	417,318	428,967
	Investment in FDR/ other deposits	208,702	208,335
	Impairment	(273,600)	(273,600)
		3,645,864	3,632,438
4	Inventories		
	Raw materials	3,802,212	3,907,948
	Packing materials	762,707	743,560
	Work-in-process	498,470	635,163
	Finished goods	3,711,393	3,293,828
	Goods in transit	531,692	608,197
	Stores and spares	222,115	221,170
	Allowance for inventory	(559,016)	(699,474)
		8,969,573	8,710,393

	30 September 2024	Figures in '000' Taka
	Taka	30 June 2024
	Taka	Taka
4 (a) Consolidated inventories		
Raw materials	6,627,568	6,963,885
Packing materials	901,089	885,774
Work-in-process	791,381	924,843
Finished goods	12,787,528	11,711,683
Goods in transit	1,433,910	1,510,211
Stores and spares	566,724	435,915
Allowance for inventory	(987,514)	(1,142,160)
	22,120,687	21,290,152
5 Trade receivables		
Debts due over six months	1,655,433	1,664,948
Debts due below six months	3,204,708	3,181,230
Provision for doubtful debts	(849,612)	(809,299)
	4,010,529	4,036,880
5 (a) Consolidated trade receivables		
Debts due over six months	4,631,045	4,664,177
Debts due below six months	15,905,864	14,493,790
Provision for doubtful debts	(1,508,692)	(1,518,138)
	19,028,217	17,639,830
6 Inter-company receivables		
ACI Logistics Limited	13,805,431	13,385,397
ACI HealthCare Limited	13,310,600	12,426,471
ACI Foods Limited	2,937,124	2,431,888
ACI Biotech Limited	1,699,763	1,606,226
ACI Agrolink Limited	1,086,359	930,357
ACI HealthCare USA Inc.	1,059,439	1,044,946
Infolytx Bangladesh Limited	944,314	911,264
ACI Chemicals Limited	281,296	274,529
ACI Premio Plastics Limited	1,334,593	1,115,467
ACI Godrej Agrovvet (Pvt.) Limited	935	935
Computer Technology Limited	30	30
	36,459,896	34,127,510
7 Advances, deposits and prepayments		
Advances to staff, suppliers and others	570,847	450,028
VAT current account	123,709	93,191
LC Margin	666,916	1,013,054
Deposits	285,585	298,538
Prepayments	98,174	63,489
	1,745,231	1,918,300

	30 September 2024	Figures in '000' Taka
	Taka	30 June 2024
		Taka
7 (a) Consolidated advances, deposits and prepayments		
Advances to staff, suppliers and others	1,253,549	1,236,460
VAT current account	172,525	119,093
LC Margin	3,264,311	2,211,995
Deposits	943,713	825,513
Prepayments	244,110	219,002
Advance for capital expenditure	22,600	19,532
	5,900,808	4,631,596
8 Employee benefits		
Staff gratuity provision	1,342,610	1,251,874
Other long term employee benefits	321,556	306,578
	1,664,166	1,558,453
8 (a) Consolidated employee benefits		
Staff gratuity provision	1,678,527	1,567,375
Other long term employee benefits	443,289	419,452
	2,121,816	1,986,827
9 Long term borrowings		
Long term bank loans	1,632,161	1,692,941
	1,632,161	1,692,941
9 (a) Consolidated long term borrowings		
Long term bank loans	6,394,868	6,943,562
	6,394,868	6,943,562
10 Loans and borrowings - short term		
Short term loans	27,682,104	26,646,291
Current portion of long term loans	683,045	588,951
	28,365,149	27,235,242
10 (a) Consolidated loans and borrowings - short term		
Short term loans	47,487,056	43,934,229
Current portion of long term loans	4,262,628	4,086,107
	51,749,684	48,020,336
11 Inter company payables		
ACI Marine and Riverine Technologies Limited	10,430	39,515
ACI Motors Limited	483,341	499,653
ACI Salt Limited	1,604,373	2,022,518
ACI Pure Flour Limited	1,634,041	1,836,071
ACI Edible Oils Limited	256,771	273,399
Creative Communication Limited	23,701	33,155
ACI Formulations Limited	1,585,931	1,554,359
Stochastic Logic Limited	2,758	2,765
	5,601,347	6,261,434

	30 September 2024	Figures in '000' Taka
	Taka	30 June 2024
		Taka
12 Other payables		
Accruals	2,583,518	2,138,066
Advance from customers	76,387	78,393
Security money received from customers	34,508	36,907
Workers' profit participation fund	1,047,589	985,324
Tax and VAT deducted at source	157,587	130,101
Employees welfare fund	376,758	362,715
Rights share deposit to be refunded	564	564
Family day fund	7,777	7,491
Non-management staff provident fund	70,173	65,148
Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	20,403	20,403
Management staff provident fund	23,413	44,124
Advertisement and promotional funds	92,384	92,035
Development funds	12,179	12,358
Other finances	66,000	66,000
	4,572,888	4,043,278
12 (a) Consolidated other payables		
Accruals	6,333,858	5,360,006
Advance from customers	475,215	1,252,781
Security money received from customers	106,485	155,209
Workers' profit participation fund	1,518,401	1,320,986
Management staff provident fund	23,413	44,124
Tax and VAT deducted at source	386,401	583,098
Employees welfare fund	376,758	362,715
Rights share deposit to be refunded	564	564
Family day fund	7,777	7,491
Non-management staff provident fund	70,178	65,148
Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	20,403	20,403
Creditors for capital expenditure	16,820	18,343
Advertisement and promotional funds	92,384	92,035
Development funds	12,179	12,358
Other finances	66,000	66,000
	9,510,484	9,364,909

Figures in '000' Taka	
For the 1st quarter ended from	
July 2024	July 2023
to	to
September 2024	September 2023
Taka	Taka

13	Revenue		
	Pharmaceuticals	4,040,967	4,250,487
	Animal health	1,325,955	1,291,185
	Consumer brands	2,150,380	2,174,775
	Seeds	479,045	408,988
	Fertilizer	407,272	440,935
	Flexible packaging	1,602,599	-
	Animal genetics and others	132,641	168,033
		10,138,859	8,734,403
13 (a)	Consolidated revenue		
	Gross sales	30,484,418	31,228,576
	Inter-company sales	(774,723)	(823,280)
		29,709,695	30,405,296
14	Cost of sales		
	Opening stock	7,785,921	6,876,275
	Purchase	4,125,668	4,585,126
		11,911,589	11,461,401
	Closing stock	(7,612,704)	(7,020,713)
		4,298,885	4,440,688
	Manufacturing expenses	1,945,793	644,816
		6,244,677	5,085,503
14 (a)	Consolidated cost of sales		
	Opening stock	20,478,216	20,689,595
	Purchase	20,986,137	21,488,826
		41,464,353	42,178,420
	Closing stock	(21,109,418)	(20,903,286)
		20,354,935	21,275,134
	Manufacturing expenses	1,869,284	1,807,951
		22,224,219	23,083,086
15	Administrative, selling and distribution expenses		
	Administrative expenses	169,057	167,542
	Distribution expenses	346,486	331,754
	Selling expenses	2,157,548	2,325,438
		2,673,090	2,824,735

Figures in '000' Taka	
For the 1st quarter ended from	
July 2024	July 2023
to	to
September 2024	September 2023
Taka	Taka

15 (a) Consolidated administrative, selling and distribution expenses

Administrative expenses	612,131	756,124
Distribution expenses	678,122	642,570
Selling expenses	4,111,579	4,185,842
	5,401,832	5,584,536

16 Reconciliation of net operating cash flow

Profit after tax	731,017	568,134
<i>Adjustment for non-cash items and others:</i>		
- Unrealized gain on translation of foreign currency receivables	-	(27,302)
- Depreciation and amortisation	174,635	121,693
- Provisions	(100,145)	(46,125)
- Finance cost	276,764	100,298
- Tax expense	197,538	218,901
- Contribution to WPPF	48,871	41,423
- Lease and other adjustments	46,458	46,054
<i>Changes in:</i>		
- Inventories	(118,721)	(297,319)
- Trade and other receivables	(142,262)	(103,387)
- Advances, deposits and prepayments	(91,471)	(332,301)
- Trade and other payables, and employment benefits	376,733	695,118
Cash generated from operating activities	1,399,416	985,187
Paid to WPPF	(12,168)	(13,439)
Interest paid	(79,704)	(76,860)
Income tax paid	(281,136)	(204,748)
Net cash from operating activities	1,026,408	690,140

16 (a) Reconciliation of consolidated net operating cash flow

Profit/ (loss) after tax	(469,144)	(141,094)
<i>Adjustment for non-cash items and others:</i>		
- Depreciation and amortisation	447,229	420,224
- Provisions	(164,092)	2,558
- Share of profit of equity accounted investees	(110,091)	(157,600)
- Finance cost	2,126,202	1,534,474
- Tax expense	535,661	569,018
- Contribution to WPPF	84,049	75,909
- Lease and other adjustments	141,671	126,507

Changes in:

- Inventories	(675,888)	427,735
- Trade and other receivables	(1,512,350)	(1,416,326)
- Advances, deposits and prepayments	(1,895,930)	(1,441,174)
- Trade and other payables, and employment benefits	(674,619)	(876,208)
Net cash from operating activities	(2,167,301)	(875,978)
Paid to WPPF	(29,615)	(22,984)
Interest paid	(1,937,751)	(1,136,008)
Income tax paid	(607,844)	(577,024)
Net cash from operating activities	(4,742,511)	(2,611,994)

- 17 Consolidated operating segments
Please see Annexure A.

Figures in '000' Taka	
For the 1st quarter ended from	
July 2024	July 2023
to	to
September 2024	September 2023

- 18 Consolidated EPS, NAV per share, and NOCFPS

Ordinary shares (Number)	76,206	76,206
Number of shares in the process of issuing for Merger Consideration	195	195
Weighted average number of ordinary shares (in thousand)	76,401	76,401
Consolidated profit/ (loss) attributable to owners of the Company	(423,563)	(157,892)
Earnings per share (Taka)	(5.54)	(2.07)
Consolidated cash flows from operating activities (Taka '000)	(4,742,511)	(2,611,994)
Net operating cash flows per share (NOCFPS)	(62.07)	(34.19)
	30 September 2024	30 June 2024
	Taka	Taka
Consolidated net asset attributable to owners of the Company (Taka '000)	6,476,613	6,965,832
Net asset value (NAV) per share	84.77	91.17

Reasons for significant deviations: During the first quarter ended on 30 September 2024, the Group experienced a 2.29% decrease in revenue. This reduction was largely driven by country-wide instability, supply chain disruptions, energy shortages, and other macroeconomic challenges impacting the period. Segment level changes in revenue has been demonstrated in Annexure A: Consolidated Operating Segments. During the period, operating profit improved as a result of cost control initiatives. On the other hand, cost of borrowing increased due to the increase in market interest rate along with the additional funding for working capital and strategic investments for supporting business growth. Overall, the consolidated EPS was Taka (5.54) during the period against Taka (2.07) of SPLY. NOCFPS during the period was Taka (62.07) against Taka (34.19) as a result of the movement in the working capital level.

- 19 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A

Consolidated operating segments

Figures in '000' Taka
For the 1st quarter ended from July 2024 to September 2024

Particulars	Reportable Segment												Total reportable segments	Unallocated/ Elimination	Total
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Flexible Packaging	Consumer Plastics	HealthCare			
External revenue	4,040,967	1,325,955	2,079,617	987,484	7,535,837	1,431,458	5,657,356	557,626	2,358,641	1,430,902	744,776	15,258	28,165,877	1,543,818	29,709,695
Inter-segment revenue	-	-	214,583	-	37,367	62,917	21,756	16,952	77,881	171,697	-	110,778	713,931	60,792	774,723
Segment revenue	4,040,967	1,325,955	2,294,200	987,484	7,573,204	1,494,374	5,679,112	574,577	2,436,522	1,602,599	744,776	126,035	28,879,808	1,604,610	30,484,418
Depreciation and amortisation	83,734	7,321	20,272	5,875	34,133	8,509	42,199	24,625	23,548	43,808	24,307	98,286	416,616	30,613	447,229
Operating expenses	1,784,340	267,279	490,351	155,569	932,330	67,942	1,071,395	64,955	197,966	48,380	129,213	15,552	5,225,273	176,559	5,401,832
Finance cost / (income)	139,350	62,570	37,285	53,209	215,494	(27,231)	699,926	(32,333)	142,209	132,367	97,423	614,119	2,134,390	(8,188)	2,126,202
Segment profit/(loss) before tax	388,506	76,607	47,251	196,396	451,288	10,138	(605,242)	49,131	(77,973)	84,179	(80,486)	(785,340)	(245,547)	312,064	66,518
Segment assets at 30 September 2024	16,125,102	2,558,915	3,950,457	2,922,540	25,534,879	3,161,531	7,217,795	3,861,902	3,477,857	6,717,804	1,636,721	7,934,024	85,099,527	12,938,524	98,038,051
Segment liabilities at 30 September 2024	4,831,126	1,093,972	2,317,680	1,146,802	14,687,018	1,877,180	26,061,133	1,394,553	5,527,342	6,069,638	2,159,505	20,672,524	87,838,472	2,169,971	90,008,443

For the period up to 1st quarter from July 2023 to September 2023

Particulars	Reportable segment												Total reportable segments	Unallocated/ Elimination	Total
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Flexible Packaging	Consumer Plastics	HealthCare			
External revenue	4,250,487	1,291,185	2,096,591	1,151,644	7,067,090	1,938,738	5,018,763	898,242	2,505,558	1,235,127	509,165	746,734	28,709,326	1,695,971	30,405,296
Inter-segment revenue	-	-	270,591	-	82,430	35,788	22,598	6,602	56,211	195,649	-	126,879	796,749	26,531	823,280
Segment revenue	4,250,487	1,291,185	2,367,182	1,151,644	7,149,520	1,974,526	5,041,361	904,845	2,561,769	1,430,776	509,165	873,614	29,506,074	1,722,502	31,228,576
Depreciation and amortisation	77,406	6,576	19,828	4,808	31,241	8,582	40,717	22,857	17,005	44,106	24,550	94,595	392,270	27,954	420,224
Operating expenses	1,934,621	251,262	546,430	173,216	894,677	72,346	948,097	104,369	174,809	39,585	108,148	139,597	5,387,158	197,377	5,584,536
Finance cost / (income)	84,590	49,660	40,969	41,830	184,575	1,432	469,436	(38,215)	115,778	101,248	70,419	427,763	1,549,485	(15,011)	1,534,474
Segment profit/(loss) before tax	408,873	70,652	(893)	136,490	530,365	(15,039)	(425,917)	38,716	1,108	56,519	(96,981)	(619,290)	84,604	343,320	427,924
Segment assets at 30 June 2024	15,853,828	2,278,089	3,888,578	2,782,408	23,443,792	3,072,145	7,412,010	4,435,938	3,195,653	6,172,399	1,366,994	1,366,994	75,268,827	18,825,903	94,094,731
Segment liabilities at 30 June 2024	4,660,309	1,226,754	2,140,012	1,116,551	12,898,438	1,785,926	25,615,972	2,004,606	5,151,499	5,589,299	1,781,442	1,781,442	65,752,250	19,784,754	85,537,004